EFM
CAPR icon

E Fund Management’s Capricor Therapeutics CAPR Stock Holding History

E Fund Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205K Buy
8,513
+675
+9% +$20.5K ﹤0.01% 452
2026
Q1 		$238K Buy
+7,838
New +$209K 0.01% 428

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

E Fund Management's CAPR Position: Q2 2026 in Review

E Fund Management increased its Capricor Therapeutics (CAPR) stake by 8.6% in Q2 2026, buying an estimated $20.5K and bringing the position to 8,513 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #452.

E Fund Management first reported a position in CAPR in Q1 2026 and has held it in 2 quarters since. The position peaked at $238K in Q1 2026. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • E Fund Management held 8,513 shares of Capricor Therapeutics worth $205K as of Q2 2026.
  • E Fund Management bought 675 Capricor Therapeutics shares in Q2 2026, an estimated $20.5K.
  • Capricor Therapeutics made up ﹤0.01% of E Fund Management's portfolio in Q2 2026, its #452 holding.
  • E Fund Management first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • E Fund Management's Capricor Therapeutics position peaked at $238K in Q1 2026.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.